{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:10:07Z","timestamp":1793214607806,"version":"4.5.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.581673","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T08:34:42Z","timestamp":1605602082000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":57,"title":["Apremilast Regulates the Teff\/Treg Balance to Ameliorate Uveitis via PI3K\/AKT\/FoxO1 Signaling Pathway"],"prefix":"10.3389","volume":"11","author":[{"given":"Yuxi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenru","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102351","article-title":"Uveitis: Autoimmunity and beyond","volume":"18","author":"Bertrand","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"E134","DOI":"10.3390\/molecules22010134","article-title":"Therapeutic Potential of Targeting the Th17\/Treg Axis in Autoimmune Disorders","volume":"22","year":"2017","journal-title":"Molecules"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-019-00758-z","article-title":"Resolution of uveitis","volume":"41","author":"Wildner","year":"2019","journal-title":"Semin Immunopathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.11.056","article-title":"Phosphodiesterase 4 inhibitors","volume":"78","author":"Zebda","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2019.04.020","article-title":"cAMP\/PKA signaling compartmentalization in cardiomyocytes: Lessons from FRET-based biosensors","volume":"131","author":"Ghigo","year":"2019","journal-title":"J Mol Cell Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-015-0771-6","article-title":"Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors","volume":"17","author":"Montesinos","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00559.x","article-title":"Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis","volume":"159","author":"Schafer","year":"2010","journal-title":"Br J Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0144-3","article-title":"Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast","volume":"29","author":"Gooderham","year":"2015","journal-title":"BioDrugs"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-019-00284-1","article-title":"Apremilast Normalizes Gene Expression of In ammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice","volume":"19","author":"Adams","year":"2019","journal-title":"Drugs R&D"},{"key":"B10","doi-asserted-by":"publisher","first-page":"R107","DOI":"10.1186\/ar3041","article-title":"Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis","volume":"12","author":"McCann","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.01662","article-title":"apremilast ameliorates experimental arthritis via suppression of Th1 and Th17 cells and enhancement of cD4+Foxp3+ regulatory T cells Differentiation","volume":"9","author":"Weiqian Chen","year":"2018","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X19828669","article-title":"IL-12\/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis","volume":"11","author":"Kragstrup","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheumatic Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/BOR.0000000000000151","article-title":"New treatment paradigms in psoriatic arthritis","volume":"27","author":"Felquer","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13578-020-00416-0","article-title":"Roles of the PI3K\/AKT\/mTOR signalling pathways in neurodegenerative diseases and tumours","volume":"10","author":"Xu","year":"2020","journal-title":"Cell Bioscience"},{"key":"B16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/biom9020067","article-title":"Getting the Akt Together: Guiding Intracellular Akt Activity by PI3K","volume":"9","author":"Yudushkin","year":"2019","journal-title":"Biomolecules"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.02.049","article-title":"PI3K\/Akt Cooperates with Oncogenic Notch by Inducing Nitric Oxide-Dependent Inflammation","volume":"22","author":"Villegas","year":"2018","journal-title":"Cell Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.05.001","article-title":"Polyphenols in the treatment of autoimmune diseases","volume":"18","author":"Khan","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.02.012","article-title":"A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus","volume":"44","author":"Menon M","year":"2016","journal-title":"Immunity"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1207","article-title":"Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies","volume":"23","author":"Kelly","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2014.06.012","article-title":"Phosphodiesterase (PDE) inhibitor torbafylline (HWA 448) attenuates burn-induced rat skeletal muscle proteolysis through the PDE4\/cAMP\/EPAC\/PI3K\/Akt pathway","volume":"393","author":"Joshi","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500849","article-title":"Foxo1 Is a T Cell\u2013Intrinsic Inhibitor of the ROR\u03b3t-Th17 Program","volume":"195","author":"Lain\u00e9","year":"2015","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.02530","article-title":"Mucosal Immunity and the FOXO1 Transcription Factors","volume":"10","author":"Graves","year":"2019","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nature16486","article-title":"Graded Foxo1 activity in Treg cells differentiates tumour immunity from spontaneous autoimmunity","volume":"529","author":"Luo","year":"2016","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60761-720-4","article-title":"Autoimmunity methods and protocols","volume":"900","author":"Walker","year":"2012"},{"key":"B26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bcp.2018.04.006","article-title":"Baicalin modulates the Treg:Teff balance to alleviate uveitis by activating the aryl hydrocarbon receptor","volume":"154","author":"Zhu","year":"2018","journal-title":"Bbiochem Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-8938-6_15","article-title":"Clinical and Functional Evaluation of Ocular Inflammatory Disease Using the Model of Experimental Autoimmune Uveitis","volume":"1899","author":"Caspi","year":"2019","journal-title":"Methods Mmol Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.113645","article-title":"Teriflunomide suppresses T helper cells and dendritic cells to alleviate experimental autoimmune uveitis","volume":"170","author":"Li","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-20912","article-title":"Effect of Methotrexate on an In Vitro Patient-Derived Model of Proliferative Vitreoretinopathy","volume":"58","author":"Dhanesh Amarnani","year":"2017","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"B30","article-title":"Protective Effect of the Type IV Phosphodiesterase Inhibitor Rolipram in EAU: Protection Is Independent of IL-10-Inducing Activity","volume":"40","author":"Xu","year":"1999","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-1373","article-title":"Effects of rolipram, a selective inhibitor of type 4 phosphodiesterase, on lipopolysaccharide-induced uveitis in rats","volume":"45","author":"Chi","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002309.pub5","article-title":"Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease","volume":"9","author":"Chong","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1741-7015-11-96","article-title":"Phosphodiesterase 4-targeted treatments for autoimmune diseases","volume":"11","author":"Goldminz","year":"2013","journal-title":"BMC Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1021\/jm900210d","article-title":"Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-r Inhibitor","volume":"52","author":"Hon-Wah Man","year":"2009","journal-title":"J Med Chem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60642-4","article-title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial","volume":"380","author":"Cather","year":"2012","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.03.020","article-title":"Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses","volume":"77","author":"Abrouk","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of Apremilast for Oral Ulcers in Behcet\u2019s Syndrome","volume":"381","author":"Hatemi","year":"2019","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215437","article-title":"Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behcet\u2019s disease","volume":"78","author":"Lopalco","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/art.39120","article-title":"Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study","volume":"67","author":"Genovese","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B40","article-title":"Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis and Plaque Psoriasis","volume":"8","author":"Fala","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-015-0229-7","article-title":"Imbalance Between Th17 Cells and Regulatory T Cells During Monophasic Experimental Autoimmune Uveitis","volume":"39","author":"Zhang","year":"2015","journal-title":"Inflammation"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1102574","article-title":"Ocular immune privilege: the eye takes a dim but practical view of immunity and inflammation","volume":"74","author":"Streilein","year":"2003","journal-title":"J Leukocyte Biol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"re5","DOI":"10.1126\/scisignal.3135re5","article-title":"Phosphati- dylinositol 3-kinase signaling in thymocytes- the need for stringent control","volume":"3","author":"Moncayo","year":"2010","journal-title":"Sci Signaling"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-020-05435-1","article-title":"Role of PI3K\/AKT pathway in cancer: the framework of malignant behavior","volume":"47","author":"Jiang","year":"2020","journal-title":"Mol Biol Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0834-6","article-title":"Emerging role of PTEN loss in evasion of the immune response to tumours","volume":"122","author":"Vidotto","year":"2020","journal-title":"Br J Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1124\/pr.111.004846","article-title":"Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease","volume":"64","author":"Liby","year":"2012","journal-title":"Pharmacol Rev"},{"key":"B47","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12974-019-1474-8","article-title":"Baicalin ameliorates neuroinflammation-induced depressive-like behavior through inhibition of toll-like receptor 4 expression via the PI3K\/AKT\/FoxO1 pathway","volume":"16","author":"Guo","year":"2019","journal-title":"J Neuroinflamm"},{"key":"B48","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/cells9010184","article-title":"A Review of FoxO1-Regulated Metabolic Diseases and Related Drug Discoveries","volume":"9","author":"Peng","year":"2020","journal-title":"Cells"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201541905","article-title":"AKT isoforms modulate Th1-like Treg generation and function in human autoimmune disease","volume":"17","author":"Kitz","year":"2016","journal-title":"EMBO Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106035","article-title":"CXCL16\/CXCR6 axis promotes bleomycin-induced fibrotic process in MRC-5 cells via the PI3K\/AKT\/FOXO3a pathway","volume":"81","author":"Ma","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00796","article-title":"The Bu Shen Yi Sui\u00a0Formula Promotes Axonal Regeneration via Regulating the Neurotrophic Factor BDNF\/TrkB and the Downstream PI3K\/Akt Signaling Pathway","volume":"10","author":"Zheng","year":"2019","journal-title":"Front Pharmacol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-15460","article-title":"FoxO1 gene confers genetic predisposition to acute anterior uveitis with ankylosing spondylitis","volume":"55","author":"Yu","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.581673\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T08:34:45Z","timestamp":1605602085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.581673\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,17]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2020.581673"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.581673","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,17]]},"article-number":"581673"}}